Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw

  • Paek, Seung Jae (Department of Oral and Maxillofacial Surgery, Wonkwang University Dental Hospital) ;
  • Park, Won-Jong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University) ;
  • Shin, Ho-Sung (Department of Society Dentistry, College of Dentistry, Wonkwang University) ;
  • Choi, Moon-Gi (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University) ;
  • Kwon, Kyung-Hwan (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University) ;
  • Choi, Eun Joo (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University)
  • Received : 2016.06.06
  • Accepted : 2016.09.16
  • Published : 2016.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The objective of this study was to retrospectively investigate the association of diseases having an influence on inhibition of angiogenesis such as hypertension, diabetes mellitus type II, hypercholesterolemia, and rheumatoid arthritis (RA) with the development of osteonecrosis of the jaws. Materials and Methods: The 135 patients were allocated into 4 groups of bisphosphonate-related osteonecrosis of the jaw (BRONJ) group (1A); non-BRONJ group (1B); osteonecrosis of the jaw (ONJ) group (2A); and control group (2B), according to histologic results and use of bisphosphonate. This retrospective study was conducted with patients who were treated in one institute from 2012 to 2013. Fisher's exact test and logistic regression analysis were used to analyze the odds ratios of diseases having an influence on inhibition of angiogenesis for development of ONJ. Results: The effects of diabetes and hypertension were not statistically significant on development of ONJ. When not considering bisphosphonate use, RA exhibited a high odds ratio of 3.23 (P=0.094), while hyperlipidemia showed an odds ratio of 2.10 (P=0.144) for development of ONJ. More than one disease that had an influence on inhibition of angiogenesis showed a statistically significant odds ratio of 2.54 (P=0.012) for development of ONJ. Conclusion: Patients without diseases having an influence on inhibition of angiogenesis were at less risk for developing ONJ.

Keywords

References

  1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  2. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011;48:677-92. https://doi.org/10.1016/j.bone.2010.11.020
  3. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPGRANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012;11:401-19. https://doi.org/10.1038/nrd3705
  4. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010;68:959-63. https://doi.org/10.1016/j.joms.2009.10.010
  5. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67(5 Suppl):61-70.
  6. Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, et al. Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J Hematol Oncol 2012;5:56. https://doi.org/10.1186/1756-8722-5-56
  7. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
  8. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. https://doi.org/10.1016/j.joms.2007.08.003
  9. Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C. Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig 2014;18:1015-22. https://doi.org/10.1007/s00784-013-1060-x
  10. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci 2011;1218:62-79. https://doi.org/10.1111/j.1749-6632.2010.05835.x
  11. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6. https://doi.org/10.1038/nature04478
  12. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53. https://doi.org/10.1161/01.RES.0000137877.89448.78
  13. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61. https://doi.org/10.1124/jpet.102.035295
  14. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003;278:43603-14. https://doi.org/10.1074/jbc.M308114200
  15. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
  16. Humar R, Zimmerli L, Battegay E. Angiogenesis and hypertension: an update. J Hum Hypertens 2009;23:773-82. https://doi.org/10.1038/jhh.2009.63
  17. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735-40. https://doi.org/10.1161/hc3101.091158
  18. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension: a disease of the microcirculation? Hypertension 2006;48:1012-7. https://doi.org/10.1161/01.HYP.0000249510.20326.72
  19. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8. https://doi.org/10.1161/01.RES.85.3.221
  20. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005;23:1831-7. https://doi.org/10.1097/01.hjh.0000183524.73746.1b
  21. Pirro M, Schillaci G, Menecali C, Bagaglia F, Paltriccia R, Vaudo G, et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens 2007;25:2093-9. https://doi.org/10.1097/HJH.0b013e32828e506d
  22. Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013;62:667-76. https://doi.org/10.1016/j.jacc.2013.03.089
  23. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012;2012:918267.
  24. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373-9. https://doi.org/10.1161/hc0302.102143
  25. Brem H, Jacobs T, Vileikyte L, Weinberger S, Gibber M, Gill K, et al. Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 2003;11:85-92.
  26. Berti-Couto SA, Vasconcelos AC, Iglesias JE, Figueiredo MA, Salum FG, Cherubini K. Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats. Head Neck 2014;36:84-93. https://doi.org/10.1002/hed.23260
  27. Molcho S, Peer A, Berg T, Futerman B, Khamaisi M. Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single center study. J Clin Endocrinol Metab 2013;98:E1807-12. https://doi.org/10.1210/jc.2013-2434
  28. Ozdemir BH, Akcali Z, Haberal M. Hypercholesterolemia impairs angiogenesis in patients with breast carcinoma and, therefore, lowers the risk of metastases. Am J Clin Pathol 2004;122:696-703. https://doi.org/10.1309/HW2MYB5TVF4AM0Y4
  29. Van Belle E, Rivard A, Chen D, Silver M, Bunting S, Ferrara N, et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997;96:2667-74. https://doi.org/10.1161/01.CIR.96.8.2667
  30. Jang JJ, Ho HK, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation 2000;102:1414-9. https://doi.org/10.1161/01.CIR.102.12.1414
  31. Trape J, Morales C, Molina R, Filella X, Marcos JM, Salinas R, et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand J Clin Lab Invest 2006;66:261-7. https://doi.org/10.1080/00365510600564949
  32. Henry PD. Hypercholesterolemia and angiogenesis. Am J Cardiol 1993;72:61C-64C. https://doi.org/10.1016/0002-9149(93)90257-D
  33. Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006;73:349-54. https://doi.org/10.1016/j.jbspin.2005.10.019
  34. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31.
  35. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
  36. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64:2030-8. https://doi.org/10.1158/0008-5472.CAN-03-1945
  37. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
  38. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11. https://doi.org/10.1159/000201931
  39. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 2011;127:429-38. https://doi.org/10.1007/s10549-011-1429-y
  40. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-53. https://doi.org/10.1016/j.joms.2009.03.050
  41. Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res 2013;33:3917-24.
  42. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008;121:475-83.e3. https://doi.org/10.1016/j.amjmed.2008.01.047
  43. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70. https://doi.org/10.1007/s00198-007-0384-2
  44. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000;97:3422-7. https://doi.org/10.1073/pnas.97.7.3422
  45. Maahs MP, Azambuja AA, Campos MM, Salum FG, Cherubini K. Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. Head Neck 2011;33:199-207. https://doi.org/10.1002/hed.21422
  46. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonaterelated jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-5. https://doi.org/10.1210/jc.2006-2036
  47. Conte-Neto N, Bastos AS, Marcantonio RA, Junior EM. Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws. Head Face Med 2012;8:5. https://doi.org/10.1186/1746-160X-8-5
  48. Grana J, Mahia IV, Meizoso MO, Vazquez T. Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (Pathological fracture associated with ONJ and BP use for osteoporosis). Clin Exp Rheumatol 2008;26:384-5.

Cited by

  1. Panoramic radiographic features that predict the development of bisphosphonate-related osteonecrosis of the jaw vol.34, pp.2, 2018, https://doi.org/10.1007/s11282-017-0293-9
  2. Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients vol.14, pp.None, 2019, https://doi.org/10.2147/cia.s200455
  3. Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw vol.11, pp.1, 2016, https://doi.org/10.1038/s41598-021-02637-w